Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Reminder App to Optimize Bladder Filling During Radiotherapy for Prostate Cancer

NCT06653751 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2025-07-01
Last updated
2025-06-22

Condition(s) studied

Prostate Cancer Patients Treated by Radiotherapy

Investigational drug(s) / intervention(s)

Reminder App

Reminder App: The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.

Study summary

The primary goal of this study is to assess the impact of an app that reminds patients irradiated for high-risk prostate cancer to drink water prior to each radiotherapy session on the number of bladder volumes \<200 ml during the radiotherapy course and to demonstrate that this number is lower than without using an app (historical control group).

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Histologically proven high-risk prostate cancer 2. Indication for definitive normo-fractionated radiotherapy 3. Possession of a smart phone and the ability to use it 4. Bladder volume at CT-simulation \<200 ml 5. Male gender 6. Age ≥18 years 7. Written informed consent 8. Capacity of the patient to contract Exclusion Criteria: 1. Radiotherapy of pelvic lymph nodes 2. Expected non-compliance

Primary outcome measure(s)

  • Number of fractions with bladder volumes <200 ml at 35 fractions — through study completion, an average of 7 weeks
    The primary endpoint is the number of radiation fractions with bladder volumes \<200 ml after 35 fractions of radiotherapy. The bladder volume at each radiation fraction are calculated from the corresponding Cone-Beam Computed Tomography (CBCT).

Trial sites (5)

FacilityCityRegionStatus
Vejle Hospital, University Hospital of Southern Denmark Vejle Southern Denmark
Medical Practice for Radiotherapy and Radiation Oncology Hanover Lower Saxony
Medical School Hamburg, Schwerin Campus Schwerin Mecklenburg-Vorpommern
Malteser Hospital St. Franziskus Flensburg Schleswig-Holstein
Department of Radiation Oncology, University of Lübeck and University Medical Center Schleswig-Holstein Lübeck Schleswig-Holstein
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06653751 on ClinicalTrials.gov ↗ ← All trials in Denmark